The present invention features interferon-free therapies for the treatment ofHCV. Preferably, the treatment is over ashorter duration of treatment, such as no more than 12 weeks. In one aspect,the treatment comprises administering at least two directacting antiviral agents to a subject with HCV infection, wherein the treatmentlasts for 12 weeks and does not include administrationof either interferon or ribavirin, and said at least two direct actingantiviral agents comprise (a) Compound 1 or a pharmaceuticallyacceptable salt thereof and (b) Compound 2 or a pharmaceutically acceptablesalt thereof.